Salivary Fractalkine Differentiating Periodontitis from Periodontally Healthy Subjects

Table 2

Statistical analysis of the concentration of salivary biomarkers among all groups.

		Mean	SD	Minimum	Maximum	p-Value
CX3CL1 (ng/mL)	Control	363.779	104.932	180.930	559.114	0.000
	Stage I	670.440	266.821	279.888	981.535
	Stage II	389.303	52.618	315.846	547.628
	Stage III	939.853	242.325	628.970	1,539.470
CX3CR (pg/mL)	Control	2.634	0.958	0.573	3.775	0.000
	Stage I	7.205	3.607	2.200	15.936
	Stage II	2.842	0.468	1.234	3.455
	Stage III	10.413	6.128	3.940	21.210

ANOVA test; CX3CL1: Fractalkine ligand; CX3CR: Fractalkine receptor; SD: standard deviations; Level of significance: significant at .